Trials to achieve healthy outcomes for extremely premature babies are challenging. We work with clinicians through global partnerships, aiming to find cost-effective treatments that will reduce infant mortality and illness.

Our aim is to investigate areas of need such neonatal infection, oxygen therapy and simple cost effective measures to reduce neonatal problems.

Active trials

BOOSTII (Benefits of Oxygen Saturation Targeting, trial II) will ascertain which of two oxygen saturation ranges is better for very premature babies. Oxygen is the most common therapy for preterm infants. Doctors and nurses do not know the safe and effective level of oxygenation for these babies. Higher oxygen levels may increase retinopathy of prematurity and respiratory problems, but lower oxygen levels may affect other long-term outcomes. BOOST II has recruited 1135 infants in Australia (a total of 1475 with the recruitment by our colleagues in New Zealand). Go to the BOOSTII homepage here.

The Australian Placental Transfusion Study (APTS) will determine whether a 60-second delay in clamping and cutting the cord can improve the baby's blood flow to the brain and gut, reduce the need for donor blood, and reduce rates of infection, retinopathy, poor growth, death and disability in babies born more than 10 weeks early.

The data from our latest trials are being combined with data from similar trials in other countries for prospective meta-analysis of data from many thousands of patients. We have participated or taken a lead in setting up networks of investigators who are making this happen. 

Closed trials

The INIS trial (International Neonatal Immunotherapy Study) assessed the effects of nonspecific intravenous immunoglobulin in addition to antibiotics in babies with severe infections. This trial is now closed after enrolling just under 3500 infants. Our global partners are in New Zealand, the United Kingdom and Argentina.

Quick links